Stock listing
GLUE Stock Price, News, Filings & Events — Monte Rosa Therapeutics, Inc.
Selected listing: GLUE · NASDAQ · USD · US
This page tracks Monte Rosa Therapeutics, Inc.'s GLUE:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following GLUE:NASDAQ. GLUE:NASDAQ is the stock-level entry point for investors researching Monte Rosa Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Monte Rosa Therapeutics, Inc. is a public company traded under the ticker GLUE in the American market. The company has a market capitalization of approximately $1.92 billion. Monte Rosa focuses on developing innovative therapies to address unmet medical needs.

- Ticker
- GLUE:NASDAQ
- Asset type
- Stock
- Market cap
- $1.20B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Monte Rosa Therapeutics, Inc. GLUE:NASDAQ stock context
This page tracks Monte Rosa Therapeutics, Inc.'s GLUE:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following GLUE:NASDAQ. GLUE:NASDAQ is the stock-level entry point for investors researching Monte Rosa Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Monte Rosa Therapeutics, Inc. is a public company traded under the ticker GLUE in the American market. The company has a market capitalization of approximately $1.92 billion. Monte Rosa focuses on developing innovative therapies to address unmet medical needs.
Latest news from Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular ...
September 8, 2026
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patie...
August 24, 2026
Monte Rosa Therapeutics: Q2 Earnings Snapshot
August 6, 2026
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
August 6, 2026
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
May 7, 2026
Monte Rosa Therapeutics, Inc. earnings calls
Research Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for GLUE:NASDAQ.
Monte Rosa Therapeutics, Inc. company profile
View the public company page for Monte Rosa Therapeutics, Inc. on 6ix.
Monte Rosa Therapeutics, Inc. news
Read company news and market updates connected to Monte Rosa Therapeutics, Inc..
Monte Rosa Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Monte Rosa Therapeutics, Inc..